A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Registrational; Therapeutic Use
- Acronyms EXPLORER-HCM
- Sponsors MyoKardia
- 08 Apr 2024 Results of exploratory analysis assessing the effect of mavacamten on circulating biomarkers using proteomics presented at the 73rd Annual Scientific Session of the American College of Cardiology
- 14 Nov 2023 Results of prespecified post hoc analysis from explorer HCM trial assessing baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men published in the Circulation
- 13 Nov 2023 Results of exploratory subgroup analysis (n=190) assessing the effect of HCM-specific sarcomere gene variants on response to mavacamten presented at the American Heart Association Scientific Sessions 2023